发明名称 |
Substituted pyrazolo[3,4-<i>d</i>]pyrimidine compounds, their preparation and use as sigma receptors ligands |
摘要 |
The present invention relates to new substituted pyrazolo[3,4-d]pyrimidine compounds, having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments. |
申请公布号 |
US9278974(B2) |
申请公布日期 |
2016.03.08 |
申请号 |
US201314442816 |
申请日期 |
2013.11.14 |
申请人 |
LABORATORIOS DEL DR. ESTEVE S.A. |
发明人 |
Díaz Fernández José Luis;Almansa Carme;Corbera Arjona Jordi |
分类号 |
C07D293/06;C07H21/00;C07D487/04 |
主分类号 |
C07D293/06 |
代理机构 |
Hueschen and Sage |
代理人 |
Hueschen and Sage |
主权项 |
1. A compound of general formula (I):wherein
n is 1, 2, 3 or 4; R1 represents a carbon-linked substituted or unsubstituted aryl or heteroaryl radical; R2 and R3 independently represent a hydrogen atom; a branched or unbranched, saturated or unsaturated, optionally at least mono-substituted, aliphatic radical C1-10; a substituted or unsubstituted cycloalkyl radical C3-9; a branched or unbranched cycloalkyl-alkyl radical C1-10 group in which either the alkyl group and/or the cycloalkyl group is optionally at least mono-substituted; a substituted or unsubstituted cycloalkyl C3-9 or cycloalkylalkyl C1-10 group in which the cycloalkyl group is condensed with another substituted or unsubstituted mono- or polycyclic ring system; a substituted or unsubstituted aryl radical; a substituted or unsubstituted, branched or unbranched arylalkyl radical C1-10; a substituted or unsubstituted heteroaryl radical; a substituted or unsubstituted, branched or unbranched heteroarylalkyl radical C1-10; a substituted or unsubstituted non-aromatic heterocyclyl radical C3-9; a substituted or unsubstituted, branched or unbranched heterocyclylalkyl radical C3-9; a substituted or unsubstituted heterocyclyl C3-9 or heterocyclyl-alkyl radical C1-10 group in which the heterocyclyl group is condensed with another substituted or unsubstituted mono- or polycyclic ring system; or R2 and R3 together with the bridging nitrogen form a substituted or unsubstituted heterocycloalkyl radical C3-9; or a substituted or unsubstituted heteroaryl radical C3-9; or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof. |
地址 |
Barcelona ES |